Purpose of the study. To study the expression of immunophenotypic marker molecules on B-
lymphocytes of patients with chronic lymphocytic leukemia at the stages of …

Profound immunological dysfunction is the key factor determining the development of
infectious complications in chronic lymphocytic leukemia (CLL). The aim of this work is to …

Purpose of the study. To evaluate the features of morphological and immunophenotypic
characteristics of the lymphoid population with different restriction of light chains of …

The achievement of molecular remission is associated with increasing of survival of patients
with chronic lymphatic leukemia. The important direction of research is seeking of …

Genetic factors not only contribute to the development of chronic lymphocytic leukemia
(CLL), but also can affect the nature of the pathological process. The study included 30 …

Background: Up to now, the immune status of chronic lymphocytic leukemia (CLL) patients
in association with the expression of zeta-chain-associated protein kinase 70 (ZAP-70) in …

Introduction. Standard treatment for chronic lymphocytic leukemia (CLL) has experienced a
dramatic change over the last few years. Until recently, CLL was treated using …

Background: There is a need for development of new drugs for treatment of B‐cell chronic
lymphocytic leukemia (CLL), especially for poor‐prognostic subgroups resistant to …

Background B-chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in
the Western countries. Any routinely used staging system does not distinguish exactly the …

The b-cell chronic lymphatic leukemia is the most common among all lymphatic proliferative
diseases and is characterized by significant variability of its clinical course. The mutation …